Related Experiment Video

Updated: Dec 17, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.0K

A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies

Anna Hartley1, Gayatri Kavishwar1, Ilaria Salvato2

  • 1Laboratory of Oncolytic Virus Immuno-Therapeutics, German Cancer Research Center, 69120 Heidelberg, Germany;

Annual Review of Virology
|July 1, 2020
PubMed

Insights

Autonomous rodent protoparvoviruses (PVs) show promise as cancer treatments by activating the immune system. Further research is needed to improve their clinical efficacy and enable personalized PV-based cancer therapies.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Autonomous rodent protoparvoviruses (PVs) exhibit oncotropism and oncosuppressive properties, making them potential anticancer agents.
  • Viral infection by PVs can induce immunogenic cell death, stimulating an anti-tumor immune response.
  • Current clinical trial efficacy of oncolytic PVs is moderate, lagging behind preclinical findings.

Purpose of the Study:

  • To review strategies for enhancing the anticancer efficacy of oncolytic PVs.
  • To explore the role of cellular factors in the PV life cycle for personalized therapy development.
  • To identify challenges in advancing PV-based cancer treatments into clinical practice.

Main Methods:

  • Review of existing literature on oncolytic parvoviruses.
  • Analysis of strategies to improve PV oncolytic and immunostimulatory activities.
  • Investigation into cellular factors influencing PV replication and therapeutic potential.

Main Results:

  • Development of second-generation PVs with enhanced oncolytic and immunostimulatory functions.
  • Exploration of combination therapies involving PVs and other cancer treatments.
  • Identification of potential biomarkers for personalized PV-based cancer therapy.

Conclusions:

  • Enhancing oncolytic PVs through genetic modification and combination therapies can improve efficacy.
  • Understanding cellular interactions is crucial for optimizing PV-based cancer treatments.
  • Overcoming current challenges is essential for the clinical adoption of PVs as cancer therapeutics.
Keywords:
H-1PVcancer therapycombination therapyoncolytic parvovirusoncolytic virussecond-generation parvoviruses

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.4K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
867
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
6.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K